Milan, Oct. 27 (LaPresse) – “The importance of the pharmaceutical sector in a country like Italy is fundamental. It is a strategic sector that contributes significantly to the nation’s GDP. In this complex moment, there is some uncertainty regarding regulatory aspects, which need to be framed in multiple ways, both at the European level and in larger markets such as the United States or China. This is a period in which the Italian industry is valued for producing high-quality medicines and finished products, but costs have increased in many areas, and there is great attention on active ingredients. We must not forget, as happened during the pandemic, that we risk being entirely dependent on active ingredients that mainly come from China or India.”
This was stated by Health Minister Orazio Schillaci during the event The Pharmaceutical Industry: The Role of Italy and Europe Amid Tariffs, Innovation, and New Global Challenges, part of the Leader Insights series organized by BonelliErede in Rome. “A central aspect for the sector is the right to health, as recognized by Article 32 of the Constitution. It is a right that cannot depend on where a person lives, whether in the north or south, or on how much they earn. In 2024, we returned to being the second-longest-living nation in the world, but we must cope with changing demographics and cannot be complacent,” Schillaci added.